CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 4.25: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.83BCNY717.06M · vs all stocks (USD)
Trailing P/E
37.87xRevenue (TTM)
1.24BCNY184.61M · vs all stocks (USD)
Profit Margin
9.91%Beta
0.2600xvs all stocks
52-Week Change
-17.08%vs all stocks
Market Capitalization
4.83BCNY717.06M · vs all stocks (USD)
Enterprise Value
4.84BCNY718.37M · vs all stocks (USD)
Trailing P/E
37.87xForward P/E
16.75xPrice to Sales (TTM)
4.08xPrice to Book (MRQ)
2.13xEnterprise to Revenue
3.89xEnterprise to EBITDA
23.65xGross Margin
46.52%Profit Margin
9.91%Operating Margin
15.73%Return on Assets (TTM)
2.04%Return on Equity (TTM)
5.64%Revenue (TTM)
1.24BCNY184.61M · vs all stocks (USD)
Revenue per Share (TTM)
2.33CNYUpdated Aug 19, 2026Quarterly Revenue Growth
13.30%Gross Profit (TTM)
563.51MCNY83.69M · vs all stocks (USD)
EBITDA (TTM)
140.83MCNY20.92M · vs all stocks (USD)
Net Income (TTM)
123.17MCNY18.29M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
209.40%Operating Cash Flow (TTM)
232.85MCNY34.58M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-86.49MCNY-12.85M · vs all stocks (USD)
5-Year Average Dividend Yield
0.39%vs all stocks
Payout Ratio
21.74%Minority Interest (Equity)
158.45MCNYFY2025 · Dec 31, 2025Revenue
1.21BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
653.18MCNYFY2025 · Dec 31, 2025Gross Profit
552.10MCNYFY2025 · Dec 31, 2025Operating Income
102.23MCNY15.18M · vs all stocks (USD)
Pre-tax Income
108.51MCNYFY2025 · Dec 31, 2025Income Tax Expense
19.87MCNYFY2025 · Dec 31, 2025Net Income
88.65MCNYFY2025 · Dec 31, 2025EBIT
148.29MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
206.74MCNYFY2025 · Dec 31, 2025Research & Development
93.39MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
222.43MCNYFY2025 · Dec 31, 2025Other Operating Expenses
15.46MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
4.29MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
39.78MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.1800CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.1800CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
515.19MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
515.19MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
88.65MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
4.09MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
14.11MCNYFY2025 · Dec 31, 2025Free Cash Flow
-204.75MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
231.77MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
88.65MCNYFY2025 · Dec 31, 2025Other Non-cash Items
46.51MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-105.11MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-15.94MCNYFY2025 · Dec 31, 2025Capital Expenditures
-218.86MCNYFY2025 · Dec 31, 2025Net Acquisitions
-870.00KCNYFY2025 · Dec 31, 2025Sale of Investments
24.43MCNYFY2025 · Dec 31, 2025Other Investing Activity
-52.09MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-247.38MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
518.68MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-361.89MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-37.42MCNYFY2025 · Dec 31, 2025Other Financing Charges
-12.04MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
107.34MCNYFY2025 · Dec 31, 2025Shares Outstanding
562.87MSharesUpdated Aug 19, 2026Float Shares
431.45MSharesUpdated Aug 19, 2026% Held by Insiders
27.37%vs all stocks
% Held by Institutions
0.36%vs all stocks
Total Cash (MRQ)
800.42MCNY118.88M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.42CNYUpdated Aug 19, 2026Total Debt (MRQ)
574.69MCNY85.35M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2332xCurrent Ratio (MRQ)
2.39xBook Value per Share (MRQ)
4.09CNYUpdated Aug 19, 2026Total Assets
3.35BCNY497.17M · vs all stocks (USD)
Total Current Assets
1.38BCNYFY2025 · Dec 31, 2025Total Liabilities
930.36MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.97BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
355.97MCNYFY2025 · Dec 31, 2025Total Current Liabilities
574.39MCNYFY2025 · Dec 31, 2025Cash
252.85MCNYFY2025 · Dec 31, 2025Cash Equivalents
42.58MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
295.44MCNYFY2025 · Dec 31, 2025Other Short-term Investments
379.75MCNYFY2025 · Dec 31, 2025Accounts Receivable
254.20MCNYFY2025 · Dec 31, 2025Inventory
383.75MCNYFY2025 · Dec 31, 2025Accounts Payable
214.38MCNYFY2025 · Dec 31, 2025Short-term Debt
265.40MCNYFY2025 · Dec 31, 2025Other Current Liabilities
3.13MCNYFY2025 · Dec 31, 2025Long-term Debt
250.95MCNYFY2025 · Dec 31, 2025Common Stock (Book)
562.87MCNYFY2025 · Dec 31, 2025Retained Earnings
829.82MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.42BCNY359.00M · vs all stocks (USD)
52-Week Low
7.08CNYUpdated Aug 19, 202652-Week High
11.38CNYUpdated Aug 19, 202652-Week Change
-17.08%vs all stocks
Beta
0.2600xvs all stocks
50-Day MA
7.94CNYUpdated Aug 19, 2026200-Day MA
8.93CNYUpdated Aug 19, 2026Avg 10-Day Volume
24.26MSharesUpdated Aug 19, 2026Avg 30-Day Volume
21.98MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
0.2300CNYUpdated Aug 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 4.25: safe zoneNotable
Altman Z-Score: 4.25
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Shattuck Labs Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Teyi Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Wecome Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Aura Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Lifotronic Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ceribell, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hvsen Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Climb Biotherapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Getein Biotech Inc.
Tier 1ProductionApproval-Gated PipelineRule
Senores Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow